US20060258686A1
(en)
*
|
1998-05-29 |
2006-11-16 |
Cheresh David A |
Method of treatment of myocardial infarction
|
US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
WO2000042213A1
(en)
|
1999-01-13 |
2000-07-20 |
The Research Foundation Of State University Of New York |
A novel method for designing protein kinase inhibitors
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
ATE253918T1
(de)
|
1999-12-08 |
2003-11-15 |
Centre Nat Rech Scient |
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
|
AU8473401A
(en)
*
|
2000-08-04 |
2002-02-18 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
DE60236646D1
(de)
*
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
EP1385862A4
(en)
*
|
2001-04-13 |
2005-03-02 |
Human Genome Sciences Inc |
VASCULAR ENDOTHEL GROWTH FACTOR 2
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
ATE323702T1
(de)
|
2002-08-06 |
2006-05-15 |
Astrazeneca Ab |
Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
|
PL377847A1
(pl)
|
2003-01-14 |
2006-02-20 |
Arena Pharmaceuticals Inc. |
1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
|
JP4960085B2
(ja)
*
|
2003-03-19 |
2012-06-27 |
エクセリクシス, インク. |
Tie−2モジュレータと使用方法
|
US20050008640A1
(en)
*
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
EA010023B1
(ru)
*
|
2003-07-14 |
2008-06-30 |
Арена Фармасьютикалз, Инк. |
Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
JP2007520559A
(ja)
*
|
2004-02-03 |
2007-07-26 |
アボット・ラボラトリーズ |
治療薬としてのアミノベンゾオキサゾール類
|
EP1831225A2
(en)
*
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
NZ598441A
(en)
*
|
2005-02-16 |
2013-07-26 |
Anacor Pharmaceuticals Inc |
Boron-containing small molecules
|
EP1932839A4
(en)
*
|
2005-09-06 |
2014-09-10 |
Shionogi & Co |
INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
|
EP2385053B1
(en)
*
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
PT3184526T
(pt)
|
2005-12-13 |
2018-12-19 |
Incyte Holdings Corp |
Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
|
WO2007087068A2
(en)
*
|
2006-01-13 |
2007-08-02 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
EP1981890A2
(en)
*
|
2006-01-25 |
2008-10-22 |
OSI Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
EP2001880A2
(en)
*
|
2006-03-07 |
2008-12-17 |
Array Biopharma, Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
EA200870409A1
(ru)
|
2006-04-04 |
2009-04-28 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Антагонисты киназы pi3
|
TW200806637A
(en)
*
|
2006-05-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Synthesis of triazole compounds that modulate HSP90 activity
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
ATE510536T1
(de)
*
|
2006-08-16 |
2011-06-15 |
Action Medicines Sl |
Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
|
PT2526933E
(pt)
*
|
2006-09-22 |
2015-06-23 |
Pharmacyclics Inc |
Inibidores da tirosina-quinase de bruton
|
CA2668286C
(en)
*
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
EP2099444A4
(en)
*
|
2006-12-14 |
2012-11-07 |
Nps Pharma Inc |
USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
|
US20100150863A1
(en)
|
2006-12-20 |
2010-06-17 |
Bayer Pharmaceuticals Corporation |
Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
|
WO2008082856A1
(en)
*
|
2006-12-26 |
2008-07-10 |
Pharmacyclics, Inc. |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
WO2008093246A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
US20120101113A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2008153701A1
(en)
*
|
2007-05-24 |
2008-12-18 |
Schering Corporation |
Compounds for inhibiting ksp kinesin activity
|
US20080312259A1
(en)
|
2007-06-13 |
2008-12-18 |
Incyte Corporation |
SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
JP2011507850A
(ja)
*
|
2007-12-21 |
2011-03-10 |
ザ スクリプス リサーチ インスティチュート |
Rhoキナーゼインヒビターとしてのアニリドおよびアナログ
|
US20110150833A1
(en)
*
|
2007-12-21 |
2011-06-23 |
The Scripps Research Institute |
Benzopyrans and analogs as rho kinase inhibitors
|
MX2010007418A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8993580B2
(en)
*
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
MX2010010300A
(es)
*
|
2008-03-19 |
2010-10-26 |
Osi Pharm Inc |
Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
|
US20100101977A1
(en)
*
|
2008-06-05 |
2010-04-29 |
United Comb & Novelty Corporation |
Stackable Packaging For Lipped Containers
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
AU2009270856B2
(en)
|
2008-07-16 |
2013-07-25 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
*
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
AU2009308687A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Chemocentryx, Inc. |
Compounds for the treatment of osteoporosis and cancers
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
CN106967070A
(zh)
|
2009-05-22 |
2017-07-21 |
因塞特控股公司 |
作为jak抑制剂的化合物
|
ES2487542T3
(es)
|
2009-05-22 |
2014-08-21 |
Incyte Corporation |
Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
BR112012007137A2
(pt)
|
2009-09-30 |
2015-09-15 |
Harvard College |
metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
US9062076B2
(en)
|
2009-10-22 |
2015-06-23 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
EP3378854B1
(en)
|
2010-01-27 |
2022-12-21 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
JP2013519685A
(ja)
*
|
2010-02-11 |
2013-05-30 |
ヴァンダービルト ユニバーシティー |
mGluR4アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法
|
TWI766281B
(zh)
*
|
2010-03-10 |
2022-06-01 |
美商英塞特控股公司 |
作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
US9096531B2
(en)
|
2010-05-24 |
2015-08-04 |
Toa Eiyo Ltd. |
Fused imidazole derivative
|
EA201890869A3
(ru)
|
2010-06-03 |
2019-03-29 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk)
|
JP5810157B2
(ja)
*
|
2010-07-09 |
2015-11-11 |
ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ |
プロテインキナーゼ阻害剤および処置の方法
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
EP2726634B1
(en)
|
2011-07-01 |
2017-02-22 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
|
WO2013010136A2
(en)
|
2011-07-13 |
2013-01-17 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
MY192354A
(en)
|
2011-07-19 |
2022-08-17 |
Merck Sharp & Dohme |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AU2012341028C1
(en)
*
|
2011-09-02 |
2017-10-19 |
Mount Sinai School Of Medicine |
Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
ES2627820T3
(es)
|
2011-09-13 |
2017-07-31 |
Pharmacyclics, Inc. |
Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
|
CA2853806C
(en)
|
2011-11-02 |
2020-07-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
CA2854188A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
AU2012340200B2
(en)
|
2011-11-17 |
2017-10-12 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-Terminal Kinase (JNK)
|
PL2780015T3
(pl)
|
2011-11-18 |
2017-06-30 |
Heptares Therapeutics Limited |
Agonisty receptora muskarynowego M1
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013113097A1
(en)
*
|
2012-01-31 |
2013-08-08 |
Beta Pharma Canada Inc. |
Cyclic molecules as bruton's tyrosine kinase inhibitors
|
US9045403B2
(en)
|
2012-02-29 |
2015-06-02 |
Coyote Pharmaceuticals, Inc. |
Geranyl geranyl acetone (GGA) derivatives and compositions thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
CN104379586B
(zh)
*
|
2012-05-31 |
2018-01-16 |
制药科学公司 |
蛋白激酶抑制剂
|
CA3015208C
(en)
|
2012-06-04 |
2024-01-02 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
JP6327713B2
(ja)
*
|
2012-07-27 |
2018-05-23 |
国立研究開発法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
WO2014052669A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
US9119808B1
(en)
|
2012-10-08 |
2015-09-01 |
Coyote Pharmaceuticals, Inc. |
Treating neurodegenerative diseases with GGA or a derivative thereof
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
WO2014063061A1
(en)
*
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
SG11201503695XA
(en)
|
2012-11-15 |
2015-06-29 |
Incyte Corp |
Sustained-release dosage forms of ruxolitinib
|
BR112015011171A2
(pt)
|
2012-11-15 |
2017-07-11 |
Pharmacyclics Inc |
compostos de pirrolopirimidina como inibidores da quinase
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
HUE057262T2
(hu)
|
2013-03-06 |
2022-04-28 |
Incyte Holdings Corp |
Eljárás és köztitermékek JAK inhibitor elõállítására
|
CN105246511A
(zh)
|
2013-03-06 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
TWI629275B
(zh)
*
|
2013-03-13 |
2018-07-11 |
賽諾菲公司 |
N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
CN105209042B
(zh)
|
2013-03-22 |
2019-03-08 |
米伦纽姆医药公司 |
催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
US9421208B2
(en)
|
2013-08-02 |
2016-08-23 |
Pharmacyclics Llc |
Methods for the treatment of solid tumors
|
US9655854B2
(en)
|
2013-08-07 |
2017-05-23 |
Incyte Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
ES2709509T3
(es)
|
2013-08-12 |
2019-04-16 |
Pharmacyclics Llc |
Procedimientos para el tratamiento de cáncer amplificado por HER2
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ES2676734T3
(es)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
|
JP6491202B2
(ja)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
|
CA2928721C
(en)
|
2013-10-25 |
2020-12-22 |
Pharmacyclics Llc |
Use of ibrutinib for treating and preventing chronic graft versus host disease
|
JP2016540053A
(ja)
|
2013-12-05 |
2016-12-22 |
アセルタ ファーマ ビー.ブイ. |
Pi3k阻害剤とbtk阻害剤の治療的組み合わせ
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
AP2016009297A0
(en)
|
2014-02-03 |
2016-06-30 |
Cadila Healthcare Ltd |
Novel heterocyclic compounds
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
US9775844B2
(en)
|
2014-03-19 |
2017-10-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
GB201410430D0
(en)
*
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
US9949971B2
(en)
|
2014-06-17 |
2018-04-24 |
Acerta Pharma B.V. |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US9545407B2
(en)
|
2014-08-07 |
2017-01-17 |
Pharmacyclics Llc |
Formulations of a bruton's tyrosine kinase inhibitor
|
HUE056329T2
(hu)
|
2014-08-11 |
2022-02-28 |
Acerta Pharma Bv |
BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US10196397B2
(en)
|
2014-11-19 |
2019-02-05 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of ibrutinib
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2016106628A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
WO2016115869A1
(zh)
*
|
2015-01-21 |
2016-07-28 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
KR20170122220A
(ko)
|
2015-03-03 |
2017-11-03 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나제 저해제의 약제학적 제제
|
MA41828A
(fr)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
CA2978518C
(en)
|
2015-03-27 |
2023-11-21 |
Nathanael S. Gray |
Inhibitors of cyclin-dependent kinases
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
SI3310760T1
(sl)
|
2015-06-22 |
2023-02-28 |
Arena Pharmaceuticals, Inc. |
Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
|
PL3317281T3
(pl)
|
2015-07-02 |
2020-11-02 |
Acerta Pharma B.V. |
Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
CA2998469A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
AU2016322063A1
(en)
|
2015-09-16 |
2018-04-12 |
Loxo Oncology, Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
CA3008488C
(en)
|
2015-12-16 |
2023-10-10 |
Loxo Oncology, Inc. |
Compounds useful as kinase inhibitors
|
JP6950897B2
(ja)
|
2016-01-21 |
2021-10-13 |
ジーボ・バイオポーラー・チャンシェン・ファーマシューティカル・カンパニー・リミテッドZibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
ブルトン型チロシンキナーゼ阻害剤
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
CN109153665B
(zh)
|
2016-03-03 |
2021-10-15 |
拜耳医药股份有限公司 |
新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
|
WO2017156495A1
(en)
|
2016-03-11 |
2017-09-14 |
Corvus Pharmaceuticals, Inc. |
Compounds and methods for modulating bruton's tyrosine kinase
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
EP3448390A1
(en)
|
2016-04-29 |
2019-03-06 |
Dana-Farber Cancer Institute, Inc. |
Hck as a therapeutic target in myd88 mutated diseases
|
CN105820184A
(zh)
*
|
2016-05-06 |
2016-08-03 |
蚌埠中实化学技术有限公司 |
一种4-苯氧基苯硼酸的制备方法
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
BR112019012682A2
(pt)
|
2016-12-23 |
2019-12-17 |
Arvinas Operations Inc |
moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
|
CN110546133A
(zh)
|
2017-02-03 |
2019-12-06 |
塞尔塔治疗有限公司 |
抗纤维化化合物
|
KR20190116416A
(ko)
|
2017-02-16 |
2019-10-14 |
아레나 파마슈티칼스, 인크. |
원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
|
AU2018275552B2
(en)
|
2017-06-01 |
2022-01-20 |
Bristol-Myers Squibb Company |
Substituted nitrogen containing compounds
|
EA202090485A1
(ru)
|
2017-08-14 |
2020-05-27 |
Эпизайм, Инк. |
Способы лечения рака путем ингибирования setd2
|
CN107550905B
(zh)
*
|
2017-09-11 |
2020-07-17 |
浙江永宁药业股份有限公司 |
多取代吡咯并吡啶类化合物的药物用途及其制备方法
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
US11338242B2
(en)
*
|
2017-12-27 |
2022-05-24 |
Renaissance Energy Research Corporation |
Method and apparatus for removing CO2
|
US11970482B2
(en)
|
2018-01-09 |
2024-04-30 |
Ligand Pharmaceuticals Inc. |
Acetal compounds and therapeutic uses thereof
|
CN112105608B
(zh)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
|
AU2019245420A1
(en)
|
2018-03-30 |
2020-11-12 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using JAK inhibitors
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
JP2021536428A
(ja)
*
|
2018-08-14 |
2021-12-27 |
エピザイム,インコーポレイティド |
置換インドール及びその使用方法
|
WO2020079652A1
(en)
|
2018-10-17 |
2020-04-23 |
Insilico Medicine Hong Kong Limited |
Kinase inhibitors
|
CA3119390A1
(en)
|
2018-11-12 |
2020-05-22 |
Debiopharm International S.A. |
Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
AU2020228644A1
(en)
*
|
2019-02-27 |
2021-09-23 |
Optikira, LLC |
Pyrazolopyridine compounds for IRE1 inhibition
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
SG11202110085TA
(en)
*
|
2019-05-31 |
2021-10-28 |
Sichuan Haisco Pharmaceutical Co Ltd |
Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
AU2020436612A1
(en)
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022081512A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
EP4247795A1
(en)
|
2020-11-18 |
2023-09-27 |
Deciphera Pharmaceuticals, LLC |
Gcn2 and perk kinase inhibitors and methods of use thereof
|
CN114751927B
(zh)
*
|
2022-03-08 |
2023-10-31 |
中山大学 |
一种硼酸化合物、制备方法及用途
|
CN115124486A
(zh)
*
|
2022-07-07 |
2022-09-30 |
武汉理工大学 |
苯并噁唑衍生物及其制备方法与应用
|